Nick Golding



T +61 3 8638 0715
M +61 474 206 667

Nick is an equity capital markets specialist and regularly acts for issuers, underwriters and investors in public and private market transactions. Nick has also assisted clients on a wide range of other matters including private mergers and acquisitions, shareholder arrangements, venture capital investments, commercial contracting, debt capital markets, restructures, and general contractual, governance and securities law advice.

Nick has particular expertise acting for issuers and underwriters on pre-IPO convertible notes offerings, small and mid-market IPOs and secondary capital raisings. He has also been involved in some of the largest, most complex and innovative capital markets transactions in the Australian market.

Nick is ranked as a “Recommended” corporate lawyer in the peer-reviewed Doyle’s Guide (since 2017) and is listed in the 2020 and 2021 editions of Australia’s Best Lawyers for M&A and ECM law.

Nick Golding

Nick’s experience includes advising on the following transactions:

  • Acting for issuers on three confidential pre-IPO convertible note rounds (December 2020, February 2021, March 2021) raising a total of ~$30 million.
  • PointsBet Holdings Limited (ASX: PBH):
    • pre-IPO convertible note round raising $25 million (2018);
    • IPO raising $75 million (June 2019);
    • placement and rights issue raising $122 million (October 2019); and
    • placement and rights issue raising $353 million (September 2020).
  • Forbidden Foods Limited (ASX: FFF):
    • pre-IPO convertible note round raising $2 million (December 2019); and
    • IPO raising $6 million (August 2020).
  • Telix Pharmaceuticals Limited (ASX: TLX):
    • pre-IPO equity round raising $8 million (January 2017);
    • IPO raising $50 million (November 2017);
    • placement and share purchase plan raising $45 million (July 2019);
    • placement and strategic investment raising $40 million (September 2020); and
    • ongoing corporate and securities law advice.
  • Cynata Therapeutics Limited (ASX: CYP):
    • placement and SPP raising $8.5 million (May 2020);
    • takeover defence role relating to a $200 million indicative offer from Dainippon Sumitomo Pharma (June 2019);
    • placement to Fidelity International (May 2018);
    • placement (led by Bioscience Managers) and SPP raising $18 million (October 2020); and
    • ongoing corporate and securities law advice.
  • Amplia Therapeutics Limited (ASX: ATX):
    • rights issue and placement raising $2.5 million (July 2019); and
    • rights issue raising $4 million (July 2020);
    • ongoing corporate and securities law advice.
  • EVZ Limited’s two placements in 2018 and renounceable entitlement offer, placement and debt to equity conversion (2017).
  • Multiple capital raisings for Adslot Limited in 2018 and 2019.
  • Proserpine Capital’s $25 million recapitalisation of Condor Energy Services (2018).
  • Lithium Power International’s share placement, share purchase plan and option offer (2016) and share placement and option offer (2017), each of which required the issue of a prospectus, and its option underwriting (2017) and placement (2020).
  • Regular mandates acting as underwriter’s counsel for brokers including Wilsons Corporate Finance, Canaccord Genuity, Ord Minnett, Macquarie, Euroz Securities, Morgans, Henslow and Hartleys on IPOs and all forms of secondary capital raisings.
  • NYSE-listed Genpact Limited’s acquisition of the assets of NASDAQ-listed Fiserv Inc.’s Australian cheque processing business.
  • kikki.K’s Series A funding round to TDM Asset Management.
  • Issuer’s counsel on the following IPOs (during time spent at Herbert Smith Freehills):
    • Integral Diagnostics (2015);
    • Mitula Group (2015);
    • SpeedCast International (2014); and
    • Aconex (2014);
  • Issuer’s counsel on the roll-up acquisitions and IPOs undertaken by iCar Asia (2012) and iBuy Group (2013) and all subsequent capital raisings undertaken by them (up to mid 2016).
  • Assisting on the DDC process for Murray Goulburn’s initial public offering of units in the MG Unit Trust.
  • Ridgeback Capital Investments’ shareholder-approved $15 million share, warrant and convertible note investment into Prima BioMed.
  • The scoping study phase of the Medibank privatization.
  • The private equity vendors on certain aspects of the IPOs of Asaleo Care and Estia.

Nick holds Law and Arts degrees from the University of Western Australia